| 中文名称: | Miransertib hydrochloride | 中文别名: | Miransertib hydrochloride |
|---|---|---|---|
| 英文名称: | Miransertib hydrochloride | CAS: | 1313883-00-9 |
| 产品分类: | 纯度: | ≥99% |
| 产品编号 | 品牌 | 纯度 | 规格 | 库存 | 价格 |
|---|---|---|---|---|---|
| M413976 | 阿拉丁 | ≥99% | 100mg | 现货 | 5,149.90 元 |
| M413976 | 阿拉丁 | ≥99% | 10mg | 现货 | 1,174.90 元 |
| M413976 | 阿拉丁 | ≥99% | 250mg | 现货 | 10,299.90 元 |
| M413976 | 阿拉丁 | ≥99% | 25mg | 现货 | 1,752.90 元 |
| M413976 | 阿拉丁 | ≥99% | 50mg | 现货 | 3,295.90 元 |
| M413976 | 阿拉丁 | ≥99% | 5mg | 现货 | 608.90 元 |
| 标准名称: | Miransertib (ARQ 092) HCl | 英文名称: | Miransertib HCl |
|---|---|---|---|
| CAS: | 1313883-00-9 | 分子式: | C27H25ClN6 |
| 分子量: | 468.980603933334 | 颜色与性状: | |
| 密度: | 沸点: | ||
| 熔点: | 水溶性: |
中文名:Miransertib hydrochloride
英文名:Miransertib hydrochloride
纯度:≥99%
货号:M413976
Cas号:1313883-00-9
存储温度:-20°C储存
运输条件:超低温冰袋运输
产品介绍:
Information
Miransertib (ARQ 092) HCl is a novel, orally bioavailable and selectiveAKT pathwayinhibitor exhibiting a manageable safety profile among patients with advanced solid tumors.
Targets
Akt2 (Cell-free assay); Akt1 (Cell-free assay); Akt3 (Cell-free assay) 4.5 nM; 5 nM; 16 nM
In vitro
ARQ 092 blocks membrane translocation of inactive AKT and even dephosphorylates the membrane-associated active form, thereby perturbing AKT activity. Treatment with 50-500 nM ARQ 092 significantly blocks αMβ2 integrin function in neutrophils and reduces P-selectin exposure and glycoprotein Ib/IX/V-mediated agglutination in platelets. In a large panel of diverse cancer cell lines, ARQ 092 inhibits proliferation across multiple tumor types but are most potent in leukemia, breast, endometrial, and colorectal cancer cell lines. Moreover, inhibition by ARQ 092 is more prevalent in cancer cell lines containing PIK3CA/PIK3R1 mutations compared to those with wt-PIK3CA/PIK3R1 or PTEN mutations. ARQ 092 targets the PI3K/AKT pathway and AKT specifically and reduces phosphorylation of GSK3α and GSK3β in mutation-positive cells.
In vivo
Short-term oral administration of ARQ 092 or hydroxyurea, a main therapy for sickle cell disease, diminishes heterotypic cell-cell interactions in venules of sickle cell disease mice challenged with TNF-α. ARQ 092 is well tolerated at a continuous daily dose of 60 mg or a dose of 600 mg when administered once a week, for several months. ARQ 092 is likely to inhibit the activity of all AKT isoforms in intravascular cells and thereby attenuates the process of thrombosis and inflammation in SCD patients. ARQ 092 is highly active in a subset of endometrial tumors that harbor PI3K pathway gene mutations.
Cell Research(from reference)
Cell lines:MDA-MB-453 cells; NCI-H1650 cells; KU-19-19 cells
Concentrations:0, 0.012, 0.037, 0.11, 0.33, and 1 μM
Incubation Time:2 h
查看阿拉丁官网此产品相关对应页面:http://www.aladdin-e.com/zh_cn/M413976.html





公司科研试剂产品广泛应用于高等院校、科研院所以及生物医药、新材料、新能源、节能环保、航空航天等高新技术产业和战略性新兴产业相关企业的研发机构。截至2021年底,公司科研试剂常备库存产品超过7.5万种,是国内品种最齐全的试剂供应商之一;拥有注册用户超过14.5万名,直接客户有科研院所、高等院校(覆盖全部985工程大学、90%以上211工程大学)以及各战略新兴行业内创新型企业群体(覆盖220余家A股上市公司)。
| 企业认证: | 已认证 | 企业性质: | 研发贸易 |
|---|---|---|---|
| 主营产品: | 2-氨基-1-甲基-1H-咪唑-5-羧酸乙酯 ; 丙酮酸钠 ; [S(R)]-N-[(R)-[2-(二苯基膦)苯基]-1-萘基甲基]-N-甲基-2-叔丁基亚磺酰胺 ; [S(R)]-N-[(1S)-1-[2-(二环己基膦)苯基]乙基]-N-甲基-2-叔丁基亚磺酰胺 ; [S(R)]-N-[(S)-[2-(二环己基膦)苯基](5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)甲基]-2-叔丁基亚磺酰胺 ; | 供货范围: | 试剂 |
| 产品目录: | 215838 | 品牌: | 阿拉丁 |
| 纯度 | 品牌 | 规格 | 发货地 |
|---|---|---|---|
| ≥98% | 阿拉丁 | 100mg / 1g / 250mg / 25g / 5g | 上海 |